Top Page
GRI Bio
(NASDAQ:GRI)
GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)
GRI Bio Business Overview & Revenue Model
GRI Bio Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.00K | -4.00K | -57.00K | -50.00K | -73.00K | 0.00 |
| EBITDA | -11.24M | -8.20M | -10.90M | -2.51M | -9.21M | -1.46M |
| Net Income | -11.24M | -8.21M | -13.04M | -3.22M | -9.30M | -2.53M |
Balance Sheet | ||||||
| Total Assets | 4.78M | 5.74M | 2.96M | 383.00K | 218.00K | 955.00K |
| Cash, Cash Equivalents and Short-Term Investments | 4.05M | 5.03M | 1.81M | 9.00K | 90.00K | 109.00K |
| Total Debt | 84.00K | 119.00K | 14.00K | 673.00K | 3.61M | 336.00K |
| Total Liabilities | 2.79M | 1.71M | 2.70M | 2.01M | 4.94M | 2.41M |
| Stockholders Equity | 1.99M | 4.03M | 259.00K | -1.63M | -4.72M | -1.45M |
Cash Flow | ||||||
| Free Cash Flow | -9.21M | -8.61M | -9.00M | -1.09M | -847.00K | -3.71M |
| Operating Cash Flow | -9.21M | -8.61M | -8.99M | -1.08M | -847.00K | -3.71M |
| Investing Cash Flow | 0.00 | 0.00 | -8.00K | -3.00K | 0.00 | -2.00K |
| Financing Cash Flow | 8.52M | 11.83M | 10.80M | 1.01M | 600.00K | -4.00K |
GRI Bio Technical Analysis
GRI Bio Risk Analysis
GRI Bio Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.51M | -0.18 | -82.17% | ― | -3.27% | 51.83% | |
42 Neutral | $2.87M | -0.02 | -397.84% | ― | ― | 98.22% | |
33 Underperform | $2.67M | >-0.01 | -263.57% | ― | -34.58% | 96.41% | |
29 Underperform | $3.54M | -0.05 | -168.95% | ― | ― | 90.27% |
GRI Bio Corporate Events
On January 9, 2026, GRI Bio, Inc. filed a prospectus supplement to increase the maximum amount of common stock it may issue under its at-the-market offering agreement with H.C. Wainwright & Co. to an aggregate of $7.38 million in new shares, on top of approximately $6.17 million of stock already sold under the program. The company also obtained a waiver of certain provisions in a December 11, 2025 securities purchase agreement to allow further issuances under this at-the-market facility, and its counsel Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. issued a legal opinion confirming that shares sold pursuant to the program will be validly issued, fully paid and nonassessable, underscoring GRI Bio’s continued reliance on equity issuance as a funding mechanism and clarifying the legal framework for investors participating in these offerings.
The most recent analyst rating on (GRI) stock is a Hold with a $0.29 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells and a shift toward an anti-fibrotic immune profile, with increased interferon-gamma and reduced pro-fibrotic cytokines including IL-4, IL-13, IL-17A, IL-22 and TGF-β across multiple immune cell types in lung and blood samples. These mechanistic findings, which align with previously disclosed safety, tolerability and lung function benefits and suggest disease-modifying activity and fibrosis reversal, bolster clinical proof-of-concept for GRI-0621 and support its differentiation from existing IPF therapies; separately, the company noted that its December 2025 public offering has lifted stockholders’ equity above Nasdaq’s $2.5 million minimum, helping to stabilize its listing compliance position.
The most recent analyst rating on (GRI) stock is a Hold with a $0.24 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
On December 12, 2025, GRI Bio announced the closing of an $8.0 million public offering of common stock and Series F warrants, with H.C. Wainwright & Co. as the exclusive placement agent. The proceeds will support product development and corporate purposes, potentially impacting the company’s market position and operations by enhancing its financial resources.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
On December 11, 2025, GRI Bio, Inc. initiated a public offering involving shares of common stock, pre-funded warrants, and Series F warrants, aiming to raise approximately $6.7 million. The company plans to use the proceeds for working capital, product development, and general corporate purposes, with expectations to fund operations into the fourth quarter of 2026. The offering, expected to close on December 12, 2025, includes agreements with institutional investors and restrictions on further stock issuance for a specified period.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
On December 10, 2025, GRI Bio announced positive topline results from its Phase 2a clinical trial of GRI-0621 for idiopathic pulmonary fibrosis (IPF). The study met its primary and secondary endpoints, showing that GRI-0621 was well tolerated and improved biomarkers related to fibrosis and lung repair. The results suggest GRI-0621’s potential as a disease-modifying treatment for IPF, offering a promising advance in the treatment landscape and potential value for patients and shareholders.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
GRI Bio, Inc. has announced positive topline results from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The trial met its primary and certain secondary endpoints, demonstrating that GRI-0621 was well tolerated over a 12-week period and showed potential anti-fibrotic effects, with improvements in serum biomarkers and Forced Vital Capacity (FVC) in treated subjects. No serious adverse events were observed, and the findings suggest a promising impact on fibrosis resolution and lung tissue repair, potentially enhancing GRI Bio’s position in the IPF treatment market.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
On November 26, 2025, GRI Bio received a notification from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as per their quarterly report for the period ending September 30, 2025. The company has until January 10, 2026, to submit a compliance plan, which, if accepted, could grant them an extension to regain compliance. The notice does not immediately affect their listing status, but failure to comply could lead to delisting, with an option to appeal if necessary.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.